Literature DB >> 7664281

A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood.

P Brossart1, J W Schmier, S Krüger, M Willhauck, C Scheibenbogen, T Möhler, U Keilholz.   

Abstract

Malignant melanoma cells can be detected with high sensitivity in peripheral blood of patients using reverse transcription-PCR. The detection of tyrosinase mRNA that is actively expressed only in melanocytes and melanoma cells indicates the presence of melanoma cells in peripheral blood. As shown previously, tyrosinase transcripts can be found in a variety of patients with metastatic malignant melanoma. For semiquantitative analysis of these cells in peripheral blood and evaluation of possible influence of immunotherapy on the amount of circulating cells, we describe an assay combining reverse transcription-PCR and Southern blotting. In this system, the amount of circulating tumor cells was determined by interpolating the amplified tyrosinase signal strength of patient samples to an equivalent tyrosinase signal of diluted SK-mel 28 cells. We found that the amount of circulating tumor cells correlates with the tumor burden. Furthermore, in patients with regression of melanoma metastases after immunotherapy, a decrease of the amount of tumor cells in the peripheral blood was observed. Quantitative estimates of residual disease may be an accurate and sensitive predictor for the clinical course.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664281

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Digital PCR.

Authors:  B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.

Authors:  G G Wulf; B Jürgens; T Liersch; W Gatzemeier; H Rauschecker; C Buske; M Hüfner; W Hiddemann; B Wörmann
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Detection of circulating melanoma cells by immunomagnetic cell sorting.

Authors:  A Benez; A Geiselhart; R Handgretinger; U Schiebel; G Fierlbeck
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 4.  Recent advances in the care of the patient with malignant melanoma.

Authors:  D Reintgen; C M Balch; J Kirkwood; M Ross
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

5.  Development of a multiple-marker RT-PCR assay for detection of micrometastases of hepatocellular carcinoma.

Authors:  A Miyamoto; Y Fujiwara; M Sakon; H Nagano; Y Sugita; M Kondo; H Eguchi; K Dono; K Umeshita; S Nakamori; M Monden
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

6.  Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery.

Authors:  F Miyazono; S Natsugoe; S Takao; K Tokuda; F Kijima; K Aridome; S Hokita; M Baba; Y Eizuru; T Aikou
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

Review 7.  Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Authors:  P G de Takats; M V Williams; R Hawkins
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage.

Authors:  N Brouwenstijn; E H Slager; A B Bakker; M W Schreurs; C W Van der Spek; G J Adema; P I Schrier; C G Figdor
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide.

Authors:  P Brossart; M J Bevan
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

10.  Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.

Authors:  Giuseppe Palmieri; Sabrina M R Satriano; Mario Budroni; Antonio Cossu; Francesco Tanda; Sergio Canzanella; Corrado Caracò; Ester Simeone; Antonio Daponte; Nicola Mozzillo; Giuseppe Comella; Giuseppe Castello; Paolo A Ascierto
Journal:  BMC Cancer       Date:  2006-11-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.